Ca2+/カルモジュリン依存タンパク質キナーゼII (CaMKII) 標的薬の発見:課題と戦略
Xinmiao Tian1, Xianghui Wang1, Sichong Chen1
1Department of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, 110122, China.
Ageing research reviews
|September 5, 2025
まとめ
カルシウム (Ca2+) /カルモジュリン (CaM) 依存タンパク質キナーゼII (CaMKII) は,年齢関連の疾患の有望な標的である. PROTACsや遺伝子編集のような新しい戦略は,効果的なCaMKII阻害剤の開発に希望を与えます.
科学分野:
- 生物化学と分子生物学
- 薬理学と薬剤発見
- ゲロントロジーと老化に関する研究
背景:
- カルシウム (Ca2+) /カルモジュリン (CaM) 依存タンパク質キナーゼII (CaMKII) は,様々な年齢関連の疾患に関与しています.
- CaMKIIの複雑な活性化,同位体,および組織分布は,標的薬の開発に課題をもたらす.
- 現在のCaMKII阻害剤には限界があり,まだ臨床承認を得ていない.
研究 の 目的:
- 現状のCaMKII阻害剤とその限界をレビューする.
- CaMKIIを対象とした新しい治療戦略を探求する.
- より正確で効果的なCaMKII介入の開発のための革新的なアプローチを強調する.
主な方法:
- 既存のCaMKII阻害剤の作用機構による分類 (例えば,CaM結合部位阻害剤,ATP競争性阻害剤)
- PROTAC,ペプチド/核酸剤,CRISPR-Cas9遺伝子編集を含む新たな治療方法のレビュー.
- 組織特異的投与や人工薬物分子などの先進的な戦略の議論
主要な成果:
- CaMKII阻害剤には,CaM結合部位阻害剤,ATP競争性阻害剤,および基板結合部位阻害剤を含むいくつかのクラスがあります.
- 進行中の研究にも関わらず,これまでのところCaMKII阻害剤の臨床承認は得られていない.
- 革新的なアプローチは,CaMKII阻害に関連する課題を克服する見込みを示しています.
結論:
- CaMKIIは,その重要な役割のために,年齢関連の疾患の重要な治療目標です.
- PROTAC,遺伝子編集,標的型配送システムなどの新しい戦略は,改善されたCaMKII標的型治療の可能性を秘めています.
- これらの先進的なアプローチは 老化に関連した疾患に対する より正確で効果的な介入につながるかもしれません
さらに関連する動画
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
2.9K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
関連する概念動画
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
